Eye on OX40: U.S. FDA Clears IND Application for STAR-0310 in AD
The U.S. Food and Drug Administration (FDA) has cleared Astria Therapeutics Investigational New Drug (IND) application to study STAR-0310 in atopic dermatitis (AD). STAR-0310 is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. A Phase 1a trial of STAR-0310 in healthy subjects is expected to initiate in the first […]